Apalutamide – a new treatment option for prostate cancer

01/2021

MUDr. Jaromír Richter

Komplexní onkologické centrum, Nemocnice Nový Jičín

SUMMARY

Prostate cancer represents a most frequent tumor among men. Despite high success rate of locoregional treatment some patients will finally relapse and develop castration resistant disease even without metastases. Apalutamid represents a new treatment modality in the treatment of this stage of prostate cancer. Apalutamid has shown statistically significant prolongation of the median of the metastasis-free survival as well as time to symptomatic progression. Apalutamid represents new possibility in the treatment of castration resistant prostate cancer without distant metastases.

Key words

non-metastatic castration-resistant prostate cancer, nmCRPC, apalutamide, Erleada